News in Pediatric Gastroenterology Pharmacology
Different twins? Use of biosimilars in paediatric inflammatory bowel disease
HomeArchivioFascicolo 1 - Anno 2015 Gemelli diversi? I farmaci biosimilari nelle malattie infiammatorie croniche intestinali del bambino Different twins? Use of biosimilars in paediatric inflammatory bowel disease Paolo Lionetti, Silvia Ghione, Monica Paci
1Dipartimento Neurofarba, Università di Firenze - SOD Gastroenterologia, Ospedale Pediatrico Meyer, Firenze
Recently, with the expiration of pat- ents for biopharmaceutical monoclo- nal antibodies, biosimilars are coming to the market. It is likely a substantial decrease of costs of these expensive therapies. Evidence of their effective- ness and safety has been obtained from studies in adults with rheumatological disease. Extrapolation of safety and ef- ficacy to children with IBD should be done with caution. Comparative paedi- atric trials and post-marketing studies of surveillance are needed.